<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Clinical trials on FinanClub</title>
    <link>https://finan.club/tags/clinical-trials/</link>
    <description>Recent content in Clinical trials on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 27 Feb 2024 09:04:54 +0000</lastBuildDate><atom:link href="https://finan.club/tags/clinical-trials/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IBRX</title>
      <link>https://finan.club/us/ibrx/</link>
      <pubDate>Tue, 27 Feb 2024 09:04:54 +0000</pubDate>
      
      <guid>https://finan.club/us/ibrx/</guid>
      <description>score:142
Chances: Completion of enrollment for safety portions of a clinical trial is a positive indicator of progress for the company Findings from Patient-Reported Outcomes (PROs) and positive interim results from the QUILT 3.032 study showcase the potential of ImmunityBio’s therapies Acceptance for review of the Biologics License Application (BLA) for N-803 by the FDA demonstrates a significant milestone for the company Risks: The success of the clinical trials and the FDA review are crucial for the company’s future prospects, and any setbacks in these processes could impact the stock performance Competitive landscape and regulatory environment for immunotherapy companies may pose challenges Score:142 chances characters count - risks characters count = 142</description>
    </item>
    
    <item>
      <title>TGTX</title>
      <link>https://finan.club/us/tgtx/</link>
      <pubDate>Wed, 10 Jan 2024 09:03:07 +0000</pubDate>
      
      <guid>https://finan.club/us/tgtx/</guid>
      <description>score:343
Chances: TG Therapeutics, Inc. has entered into an agreement to acquire a worldwide license to Precision BioSciences, Inc.&amp;rsquo;s Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for autoimmune diseases. The average of price targets set by Wall Street analysts indicates a potential upside of 127.</description>
    </item>
    
    <item>
      <title>ARWR</title>
      <link>https://finan.club/us/arwr/</link>
      <pubDate>Thu, 04 Jan 2024 09:10:03 +0000</pubDate>
      
      <guid>https://finan.club/us/arwr/</guid>
      <description>score:114
Chances: The company has successfully priced an underwritten registered offering, indicating strong investor interest and potential for significant capital influx. The filing of an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB demonstrates progress in the company’s pipeline development.</description>
    </item>
    
  </channel>
</rss>
